drugset / Trial / NCT07499908
Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers
Timeline
- Start
- 2026-05-31
- Primary completion
- 2026-08-15
- Completion
- 2026-10-31
Publications
- Results https://doi.org/10.1080/19420862.2023.2281763
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIT-013 | Monoclonal antibody | 150 mg | Subcutaneous |
Indications
No indication recorded.